The recent submission of clinical trial data for Sanofi/Regeneron’s Dupixent and Verona’s Ensifentrine to the U.S. FDA indicates the entry of new therapies for chronic obstructive pulmonary disease (COPD) in 2024.
Sanofi is planning to expand the market for its best-selling anti-inflammatory drug Dupixent, used to treat COPD, also known as ‘smokers lung’, after a successful second phase 3 trial.
The London and New York-based gene therapy player MeiraGTx Holdings has received a $30 million investment from Sanofi in addition to potential strategic deals with the big pharma company down the road.
The modification of an existing collaboration agreement with AstraZeneca gives Sanofi full commercial control of RSV antibody Beyfortus (nirsevimab) and 'enhanced agility' in the US market.
Sanofi will acquire US-based Provention Bio: gaining Tzield (teplizumab-mzwv), which was approved by the FDA last year as the first and only therapy to delay the onset of Stage 3 type 1 diabetes.
The US Food and Drug Administration (FDA) has approved Sanofi and Sobi’s Altuviiio (efanesoctocog alfa): a first-in-class, high-sustained factor VIII replacement therapy.
The European Commission (EC) has expanded the marketing authorization for Regeneron and Sanofi’s Dupixent (dupilumab) in the European Union (EU) to treat eosinophilic esophagitis (EoE).
Phase 3 data for efanesoctocog alfa has been published in the New England Journal of Medicine (NEJM): ahead of a decision on the therapy by the US Food and Drug Administration (FDA) at the end of next month.
Sanofi Ventures has announced an additional multi-year commitment from Sanofi, with an increase in capital to more than $750m to the evergreen venture fund.
AstraZeneca and Sanofi said their Biologics License Application (BLA) for nirsevimab has been accepted for review by the US Food and Drug Administration (FDA).
Expanding generic drug competition and a decline in the demand for COVID-19 vaccines and therapies have brought down the aggregate market capitalization of the global top 20 biopharmaceutical companies by 9.1%.
The US Food and Drug Administration (FDA) has approved Provention Bio’s Tzield (teplizumab-mzwv) to delay the onset of stage 3 type 1 diabetes: with the American Diabetes Association welcoming it as a 'tremendous accomplishment'.
Sanofi and Insilico Medicine have announced a multi-year, multi-target strategic research collaboration: leveraging Insilico’s ‘Pharma.AI’ platform to advance drug development for up to six new targets.
Cholera outbreak response campaigns should now use single-dose instead of two-dose vaccination campaigns, the WHO recommends, as it highlights global cholera vaccine shortages. It is calling on the world’s leading vaccine manufacturers to step up and...
The pharmaceutical company is expanding its alliance with historically Black medical schools to bolster the battle against systemic health disparities.
The Biotechnology Innovation Organization elected the fresh slate of leaders during the BIO International Convention, taking place in San Diego this week.
Regeneron Pharmaceuticals will purchase Sanofi's stake in their collaboration on Libtayo (cemiplimab) for an upfront payment of $900m, giving Regeneron exclusive worldwide rights to the medicine.
EUROAPI has expanded a collaboration with Sanofi, which will see it support Sanofi's mRNA vaccine platform with the development of lipid nanoparticles.
Sanofi held a ground-breaking ceremony for its new vaccine facility in Singapore on April 20. The US$475m site is pegged to become fully operational by Q1 2026.
Sanofi and Blackstone today announced a strategic, risk-sharing collaboration under which funds managed by Blackstone Life Sciences will contribute up to €300m ($329m) to accelerate development for subcutaneous formulation and delivery of anti-CD38 antibody...
Releasing data from both Phase 3 and booster trials, Sanofi and GSK have announced they will submit the results as the basis for regulatory applications for their COVID-19 vaccine.
The US Food and Drug Administration (FDA) has approved Enjaymo (sutimlimab-jome) to decrease the need for red blood cell transfusion due to hemolysis in adults with cold agglutinin disease (CAD).
A single booster dose of Sanofi and GSK’s recombinant adjuvanted COVID-19 vaccine candidate delivered ‘consistently strong immune responses’, according to data released by the companies.
Sanofi and GSK announced today that their COVID-19 vaccine candidate demonstrated strong immune responses across all adult age groups in a Phase 2 trial.
Sanofi and Stanford University School of Medicine have established a three-year research collaboration: focusing on autoimmune diseases and inflammatory conditions.
Sanofi has acquired Cambridge, Massachusetts biotech Tidal Therapeutics: gaining its novel mRNA-based approach for in vivo reprogramming of immune cells.
Sanofi will build a digitally-enabled, carbon-neutral vaccine manufacturing center in Singapore: designed to respond quickly to future pandemic risks and able to produce up to four vaccines simultaneously.
A US court’s recent decision to find in favor of Sanofi and invalidate Amgen's broad antibody patent claims has biotech manufacturers concerned about how to preserve their IP.
Sanofi and GSK have initiated a new Phase 2 study for their COVID-19 vaccine candidate; with a Phase 3 study set to follow in Q2 and potential rollout of the vaccine in Q4.
Sanofi’s vaccine manufacturing plant in Marcy l’Etoile, France, will formulate and fill vials of Janssen’s COVID-19 vaccine: producing around 12 million doses a month to help address global supply demands.
Three COVID-19 vaccine manufacturing sites are set to start production in France in the coming weeks: while the French government is seeking to boost further production with a €300m ($363m) initiative announced on Monday.
French company, Sanofi, says it will support the manufacturing and supply of BioNTech’s COVID-19 vaccine, which is being co-developed with Pfizer, in a pledge to increase vaccine accessibility.
Sanofi will acquire Kymab, a clinical-stage biopharmaceutical company developing fully human monoclonal antibodies. The acquisition will give it global rights to KY1005, which has the potential to treat a range of immune-mediated diseases and inflammatory...
